We will continue to monitor trends in pricing, as reflected by the published ASP payment rates, as well as utilization within the Medicare community. In general, among the top drugs with a decrease, there are a number of competitive market factors at work – multiple manufacturers, alternative therapies or market shifts to lower priced products.ĬMS remains interested in ensuring continued beneficiary access to Part B covered drugs. Overall, the prices for 24 of the top 50 drugs decreased. The October 2021 ASP payment limits have been updated.Ĭomparing the fourth quarter 2021 payment amounts with the prior quarter reveals that, on average, payment amounts for the top 50 Part B drugs decreased by 0.6 percent.įor most of the higher volume drugs (36 out of the top 50), the prices changed 2 percent or less. The files below contain the payment amounts that will be used to pay for Part B covered drugs for the fourth quarter of 2021. ASP Drug Pricing Files October 2021 Update